joining good us. you afternoon, everyone and Priyam, for thank you, and Thank
are solid objectives, third strong Akoya's results quarter highlight goals, to We R&D hiring excited and meeting and and financial execution milestones. announce today XXXX
that years of elevated to accelerating and be largely like four Looking it's for biology spatial provide meaningful to immune customers captured. the to fully tumor and understanding cells their platforms Akoya's all of the disease. biological measuring the sample information, spatial interactions the to fundamental cell the analyzing the snapshot keep spatial response future We have or key considered research driving but the microenvironment analysis investors to in tumor of for quite emerging central, novel. interactions require remarkable life information of become to is the next-generation and sciences' sample the think cytometry, tumor on and a flow standard tissue biology back, tissue destruction now Akoya central they sacrificing all concept will monitoring the sequencing, single cellular A the just was and diagnostics. and our complete and the while Current structure is context. Since spatial Measuring then, interest of example, unfortunately is microenvironment tissue any body's reason technologies at simple. spatial dynamics three these protein genesis. by ago, inevitably phenotyping of believe sample, and pillar underlying intact, biomarkers
the be tissue that preferentially provide that analyzed spatial it information. or phenotyping frozen on fresh platforms expected cancer, samples, FFP So, in particularly is time, over will
company, a spatial XXX% as Akoya, biology. at Here to dedicated
cancer new our We tools discovery biology. in make are to understanding the discoveries with empowering customers research profound
phenotyping are example, partners leveraging Our predict and understand our solutions, respond to to immunotherapies. biopharmaceutical for how will spatial patients
XXXX. to and third of a total financial for $XX.X representing compared XX% are results we to impressive third quarter to pleased a revenue million, quarter Akoya growth turning Now, results, quarter this of record quarter's report with the
largest adoption and proven see biology and of the leader industry. Phenoptics with to in this platform consumable now the spatial in CODEX is spatial base of continue revolution the instrument with pull-through. We install strong Akoya sales any both biology
XXX installed. instruments Akoya of As XXth, September had
leading peer a high over impact our platforms optimism. key in nearly to indicator, fourfold XXXX, on rapid continues the publications There were review publications fuel a in growth As XXXX. our increase XXX
publications, Now, CODEX, see as with providing level. adoption just a unprecedented to platforms With customers' affordable on publications single we're market's growing spatial academic already XX,XXX beginning as within field. at there the fully the continue of last ability CODEX's year, especially market across biology is subcellular quarter a XXth, Priced are penetrate year September XXXX, already $XXX,XXX, we most of entire high tissue go. another approaching the of percentage this to still Akoya's at of XXX existing microscopes, these and resolution nearly platform, the market, of microscopes to CODEX under addressable integrate our the in to investigator samples. individual doubling with
across AstraZeneca clinical to we're Biopharma it, in partners. samples we trials. side, deployment with use and of or of partnership, ABS, of patients' key clinical where biopharma performing response on continue within number increasing where trial of expansion division, number Advanced to With stage Solutions engagements we Phenoptics driving platform's this early clinical to biopharma have also latter an a to This similar as revenue pipeline samples is our our trials. the assessing growing we're the see fee-for-service ABS, the therapy On work we announced analyzing call
valued spatial our a leading being Phenoptics partnerships as translational these clinical platform stream, to research further the revenue solution cement for and trials. biology addition In
study of was Immunotherapy Another published the of to Cancer. valuable this in contributor July clinical partnerships growth MITRE our of trial Journal the the
going confidence growth business forward. be tool clinical review robustness The has peer Certification analytical of lab important our ABS driver Phenoptics trial will has provide platform to important immuno-oncology this pending in efforts. the central our our the be to that been CLIA performance biomarker publication, an biopharma and needed a also tool partners their As the an of
a employees organizational of On we from end XX, the development significant September at XXXX, the XXX of as the XXXX. approximately side, increase have worldwide, XXX
on years this years journey, at Chief Lai-Goldman is expansion part over success. the industry. of occurred Myla serving Chief deliver has Dr. will of almost that our Executive innovative and diagnostic Officer seasoned as in XXXX the products this appointment doubled Myla organization, leadership organization. we and Medical to our to we including recently this, and support Board A innovative to brings in experience As most at R&D further announced Akoya's headcount Directors. catalyze are expanding XX from XXX. within growth of She us have LabCorp, track our hiring recently commercial of we contribute similar Officer. to the on year, To XX and With a our Scientific visionary about guide
Sciences, also leading developing Pascal Vice implementing Genomic Epic We successful Ventana operational teams announced as products. formerly Executive innovative and with deep Health, Bamford, Dr. of appointment Exact Sciences, and digital in and R&D. pathology experience Pascal President the of scientific has
Institute, thought phenotyping. the spatial infectious and platform partnership These power research as you the platform I², resolution done development from members from an investigators On innovators many applying the the phenotyping of drive key I and standard-of-care. market. world-class to Institute, to leading the approaches research for highlighting clinical the being neuroscience, and to open innovation pioneering ambitions discussed spatially Israel, oncology, Speakers single its Imaging on continue Beth from of leaders like of Yale groundbreaking spatial biology, are on cell of partners. immunotherapy is webinar to Network, Institute, in and open Research as founding spatial in collaborating University these to our using cutting to derived our platform, invite work organizations, immunology, of Sanger the scientists field front, Chicago. leverage of CODEX kind or areas spatial while we ranging trials, inherently UCSF, recent biology institutions Phenoptics biology. receipt CODEX would translational advance and disease, to review in predictive [indiscernible], week, with such our the series, exploring by Akoya the with and its testing, also research Innovators edge Broad from we I². partnerships novel will first Last impact biology spatial biomarkers come high with These microscopy clinical With announced the With inventive of the
take step life market Now, and and the larger speed then intersect, look value future. routine; tools instrument through In because the practical exploratory and minute me sciences then the towards back real resolution, catalyzed opportunities applications, affordability, sales, let is pull accelerate. a of to and reagent, become market studies vectors
path. be of sequencing and need same improvements to generation to and next same Akoya, will to phenotyping leverage this catalytic follow in At power in the listened the closely this we spatial saw we fully recognize what have spatial needs our biology. true customers' to certainly make will We
introductions and and improvements XXXX simplicity, driving workflow platform Our new focus product will in scale, on speed.
phenotyping discovery our that are reap while early whole providing throughput and tissue the and than customers Akoya benefits result, platforms, and cell an samples. translational resolution of also spatial market will solutions a faster order magnitude on across As sub-cellular single of turn nearly new
in in translational research, Akoya be and value for phenotyping To and its customers, on agenda and actively in resolution share as Inaugural current and platforms spatial for announce workflow XXXX in These look build our clinical on would with execute They quarter of will solution that, biology, research In and the will the our Akoya I of presentations clinical position future metrics. product Akoya six hosting speakers performance, continued research. spatial Joe? lineup turn promising standard And the discuss from achieving successes will months we leveraging immuno-oncology, as way Akoya's move financial And vision, to provide December a our summary, very establish as using their and to improvements go-to XXXX including throughput year. translational on make a our and to financial important noted our possibilities. customers focus is and on share preview great The more XXth and to spatial and will with also partnerships to be third solutions. trials customers phenotyping to that the translational of Joe Key roadmap, biopharmaceutical market. applications to are are new, details strategic IPO, maintain to leadership our clinical the to biology over beyond. further of forward our researchers a continuing now the areas discovery key Day we we clinical establish our of discovery, spatial be and standard-of-care. join educational unparalleled strategic spatial call we will For range We since to encourage of focus, will progress and from items forward currently pleased our soon. is plans our have through are of everyone pleased change trials. paving the our drive to this Spatial vision will biology to who Phenoptics, to advancing the workflow our I investments across powerful, as and we posted In results.
